Cumberland Pharmaceuticals to Announce Q3 2024 Financial Results

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company listed on Nasdaq under the symbol CPIX, announced that it will disclose its third quarter 2024 financial results and provide an update on the company's activities after the market closes on Thursday, November 7, 2024. A conference call is scheduled for the same day at 4:30 p.m. Eastern Time to discuss the financial results.

Participants interested in joining the call are required to register beforehand. Upon registration, they will receive a dial-in number and PIN, or they can opt for the "Call Me" feature to receive an automatic call at the start of the conference. 

Cumberland Pharmaceuticals is focused on delivering innovative products that enhance patient care in specific medical fields. Their operations involve the development, acquisition, and commercialization of products in markets such as hospital acute care, gastroenterology, and oncology.

Their portfolio includes several FDA-approved products:
- Acetadote® (acetylcysteine) injection, used for the treatment of acetaminophen overdose.
- Caldolor® (ibuprofen) injection, which addresses pain and fever.
- Kristalose® (lactulose) for oral solution, a prescription laxative for treating constipation.
- Sancuso® (granisetron) transdermal system, designed to prevent nausea and vomiting in patients undergoing certain chemotherapy treatments.
- Vaprisol® (conivaptan) injection, used to treat hospitalized patients with euvolemic and hypervolemic hyponatremia by increasing serum sodium levels.
- Vibativ® (telavancin) injection, intended for treating serious bacterial infections, such as hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.

Moreover, Cumberland is advancing several Phase II clinical programs that are investigating its product candidate ifetroban. These studies are focused on treating patients with Systemic Sclerosis, cardiomyopathy linked to Duchenne Muscular Dystrophy, and Idiopathic Pulmonary Fibrosis.

 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!